Cingulate Inc
NASDAQ:CING
Cingulate Inc
Total Current Assets
Cingulate Inc
Total Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Cingulate Inc
NASDAQ:CING
|
Total Current Assets
$12.7m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
67%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Total Current Assets
$55.6B
|
CAGR 3-Years
0%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-1%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Total Current Assets
$29.4B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
11%
|
|
|
Pfizer Inc
NYSE:PFE
|
Total Current Assets
$46.9B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
6%
|
CAGR 10-Years
1%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Total Current Assets
$47.6B
|
CAGR 3-Years
10%
|
CAGR 5-Years
11%
|
CAGR 10-Years
5%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Total Current Assets
$62.1B
|
CAGR 3-Years
51%
|
CAGR 5-Years
29%
|
CAGR 10-Years
17%
|
|
Cingulate Inc
Glance View
Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using Precision Timed Release, drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The company is headquartered in Kansas City, Kansas. The company went IPO on 2021-10-07. The firm is focused on the development, manufacturing and commercialization of pharmaceutical products that utilize precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles that improves the lives of patients suffering from a multitude of commonly diagnosed conditions. The company focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The firm is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). Its CTx-1301 and CTx-1302 drug candidates both contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form. Its CTx-1301 and CTx-1302 that are being developed for the treatment of ADHD, in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+).
See Also
What is Cingulate Inc's Total Current Assets?
Total Current Assets
12.7m
USD
Based on the financial report for Dec 31, 2024, Cingulate Inc's Total Current Assets amounts to 12.7m USD.
What is Cingulate Inc's Total Current Assets growth rate?
Total Current Assets CAGR 5Y
67%
Over the last year, the Total Current Assets growth was 2 088%. The average annual Total Current Assets growth rates for Cingulate Inc have been -12% over the past three years , 67% over the past five years .
